SiBone (NASDAQ:SIBN) Insider Sells 3,738 Shares of Company Stock

SiBone (NASDAQ:SIBN) insider Anshul Maheshwari sold 3,738 shares of the business’s stock in a transaction on Thursday, October 29th. The shares were sold at an average price of $22.50, for a total transaction of $84,105.00. Following the completion of the sale, the insider owned 214,497 shares in the company, valued at $4,826,182.50. This represents a 1.71% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Anshul Maheshwari also recently made the following trade(s):

• On Monday, October 5th, Anshul Maheshwari sold 1,731 shares of SiBone stock. The stock was sold at an average price of $19.50, for a total transaction of $33,754.50.
• On Friday, October 2nd, Anshul Maheshwari sold 3,318 shares of SiBone stock. The shares were sold at an average price of $18.18, for a total transaction of $60,321.24.
• On Monday, August 24th, Anshul Maheshwari sold 11,636 shares of SiBone stock. The shares were sold at an average price of $20.11, for a total transaction of $233,999.96.
• On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The stock was sold at an average price of $20.02, for a total transaction of $224,784.56.
• On Wednesday, August 19th, Anshul Maheshwari sold 5,747 shares of SiBone stock. The stock was sold at an average price of $19.55, for a total transaction of $112,353.85.
• On Monday, August 17th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The stock was sold at an average price of $18.65, for a total transaction of $87,002.25.

SiBone Price Performance

Shares of NASDAQ:SIBN traded down $1.01 during trading on Monday, reaching $20.22. The stock had a trading volume of 1,371,299 shares, compared to its average volume of 616,959. SiBone has a 52 week low of $11.48 and a 52 week high of $22.95. The business’s 50-day moving average price is $19.41 and its 200 day moving average price is $16.44. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 7.55. The stock has a market capitalization of $896.74 million, a PE ratio of -59.47 and a beta of 0.66.

SiBone (NASDAQ:SIBN) last announced its earnings results on Monday, November 2nd. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.05. The business had revenue of $55.70 million for the quarter, compared to the consensus estimate of $55.31 million. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. As a group, equities analysts predict that SiBone will post -0.40 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on SIBN. TD Cowen lifted their price objective on SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. UBS Group increased their target price on SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Weiss Ratings upgraded SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 20th. Finally, Truist Financial raised their target price on SiBone from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, October 14th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $24.50.

Hedge Funds Weigh In On SiBone

Institutional investors have recently modified their holdings of the stock. Versant Capital Management Inc lifted its position in shares of SiBone by 102.9% during the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock worth $29,000 after purchasing an additional 887 shares in the last quarter. State of Wyoming grew its stake in shares of SiBone by 70.8% during the first quarter. State of Wyoming now owns 10,832 shares of the company’s stock valued at $137,000 after purchasing an additional 4,490 shares during the last quarter. Inceptionr LLC bought a new stake in shares of SiBone during the first quarter valued at approximately $156,000. ADAR1 Capital Management LLC acquired a new stake in shares of SiBone in the first quarter valued at approximately $159,000. Finally, Elevation Point Wealth Partners LLC acquired a new stake in shares of SiBone in the first quarter valued at approximately $204,000. 98.11% of the stock is owned by institutional investors.

About SiBone

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.